AMENDMENTS TO THE CLAIMS

1. (Pending – Once Amended) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with [gossypol] (-)-gossypol, a physiologically acceptable salt of [gossypol] (-)-gossypol, gossypolone, a physiologically acceptable salt of gossypolone, or any combination thereof, which method comprises:

administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of [gossypol] (-)-gossypol, a physiologically acceptable salt of [gossypol] (-)-gossypol, gossypolone, and a physiologically acceptable salt of gossypolone, and a pharmaceutically acceptable carrier.

2. (Pending – Never Amended) The method of claim 1, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.

3. (Pending – Never Amended) The method of claim 2, wherein said cancer is adrenal cancer.

4. (Pending – Once Amended) The method of claim 1, wherein the blood concentration of said compound is [400] 200-1000 ng/dl.

5. (Pending – Never Amended) The method of claim 4, wherein said compound is gossypolone or a physiologically acceptable salt of gossypolone.

6. (Pending – Never Amended) The method of claim 5, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered orally, rectally or vaginally at a dose of 50-200 mg/d.

7. (Pending – Never Amended) The method of claim 5, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered parenterally at a dose of 1-5 mg/kg/d.

8. (Pending – Twice Amended) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with [gossypol] (-)-gossypol, a [pharmaceutically] physiologically acceptable salt of [gossypol] (-)-gossypol, or a combination thereof, which method comprises:

administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of [gossypol] (-)-gossypol and a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier.

9. (Pending – Never Amended) The method of claim 8, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.

10. (Pending – Never Amended) The method of claim 8, wherein said cancer is adrenal cancer.

11. (Pending – Once Amended) The method of claim 8, wherein the blood concentration of said compound is [400] 200-1000 ng/dl.

12. (Pending – Never Amended) The method of claim 8, wherein said compound is administered parenterally at a dose of 1-2 mg/d.

13. (Pending – Never Amended) The method of claim 8, wherein said compound is administered orally at a dose of 20-100 mg/d.

14. (Pending – Never Amended) The method of claim 8, wherein said compound is administered rectally at a dose of 40-140 mg/d.

15. The method of claim 1, wherein said cancer is a carcinoid tumor of neuroendocrine tissue located in the lung, pancreas, or gastrointestinal tract.

16. The method of claim 8, wherein said cancer is a carcinoid tumor of neuroendocrine tissue located in the lung, pancreas, or gastrointestinal tract.

17. A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, a physiologically acceptable salt of gossypol, gossypolone, a physiologically acceptable salt of gossypolone, or any combination thereof, which method comprises:

administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of gossypol, a physiologically acceptable salt of gossypol, gossypolone, and a physiologically acceptable salt of gossypolone, and a pharmaceutically acceptable carrier, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer, or said cancer is a carcinoid tumor of neuroendocrine tissue located in the lung, pancreas, or gastrointestinal tract.

18. The method of claim 17, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.

19. The method of claim 18, wherein said cancer is adrenal cancer.

20. The method of claim 17, wherein the blood concentration of said compound is 400-1000 ng/dl.

21. The method of claim 20, wherein said compound is gossypolone or a physiologically acceptable salt of gossypolone.

22. The method of claim 21, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered orally, rectally or vaginally at a dose of 50-200 mg/d.

23. The method of claim 21, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered parenterally at a dose of 1-5 mg/kg/d.

24. A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, a pharmaceutically acceptable salt of gossypol, or a combination thereof, which method comprises:

administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of gossypol and a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate or breast cancer, or said cancer is a carcinoid tumor of neuroendocrine tissue located in the lung, pancreas, or gastrointestinal tract.

25. The method of claim 24, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.

26. The method of claim 25, wherein said cancer is adrenal cancer.

27. The method of claim 24, wherein the blood concentration of said compound is 400-1000 ng/dl.

28. The method of claim 24, wherein said compound is administered parenterally at a dose of 1-2 mg/d.

29. The method of claim 24, wherein said compound is administered orally at a dose of 20-100 mg/d.

30. The method of claim 24, wherein said compound is administered rectally at a dose of 40-140 mg/d.